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Acute myeloid leukemia (AML) is a hetero­
geneous  malignant  disorder  originating  from 
mutations in progenitor cells that lead to the 
unrestrained  proliferation  of  undifferentiated 
myeloblasts (Löwenberg et al., 1999). There is 
a general consensus that the molecular events 
leading  to  AML  leukemogenesis  occur  as  a 
multistep process (Kelly and Gilliland, 2002; 
Gilliland et al., 2004). Those events are broadly 
classified into two groups: gene alterations that 
confer a proliferative and/or survival advan­
tage to hematopoietic progenitors (e.g., RAS, 
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Differentiating agents have been proposed to overcome the impaired cellular differentia-
tion in acute myeloid leukemia (AML). However, only the combinations of all-trans retinoic 
acid or arsenic trioxide with chemotherapy have been successful, and only in treating acute 
promyelocytic leukemia (also called AML3). We show that iron homeostasis is an effective 
target in the treatment of AML. Iron chelating therapy induces the differentiation of 
leukemia blasts and normal bone marrow precursors into monocytes/macrophages in a 
manner involving modulation of reactive oxygen species expression and the activation of 
mitogen-activated protein kinases (MAPKs). 30% of the genes most strongly induced by 
iron deprivation are also targeted by vitamin D3 (VD), a well known differentiating agent. 
Iron chelating agents induce expression and phosphorylation of the VD receptor (VDR), and 
iron deprivation and VD act synergistically. VD magnifies activation of MAPK JNK and the 
induction of VDR target genes. When used to treat one AML patient refractory to  
chemotherapy, the combination of iron-chelating agents and VD resulted in reversal of 
pancytopenia and in blast differentiation. We propose that iron availability modulates 
myeloid cell commitment and that targeting this cellular differentiation pathway together 
with conventional differentiating agents provides new therapeutic modalities for AML.
© 2010 Callens et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Figure 1.  Iron deprivation induces monocyte differentiation of AML cells. (a) Unsupervised microarray analysis of HL60 cells after a 48-h  
exposure to 10 µg/ml of anti-TfR1 antibody (mAb A24), 5 µM DFO, or 3 µM DFX. The color intensity represents the ratio of expression in drug-treated 
compared with control cells. The relative overexpression and underexpression compared with controls are shown in red and green, respectively (top).  
A Venn diagram of genes induced by iron deprivation (bottom) shows that only a subset of genes (105) have a shared altered expression between the JEM VOL. 207, April 12, 2010 
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Like ATRA, VD belongs to the steroid superfamily and 
plays a critical role in regulating numerous cellular and physi­
ological responses. VD associates with its cognate receptor 
(VDR) to form a heterodimer with the retinoid X receptor. 
This complex then binds to the VD responsive element, 
which is present in the promoter region of target genes, 
thereby inducing changes in gene transcription (Hughes   
et al., 2009). VD also activates a variety of protein kinases, 
such as the three families of mitogen­activated protein kinase 
(MAPK; ERK, JNK, and p38), protein kinase C, or Src fam­
ily kinases by alternative signaling pathways which are not 
fully characterized (Wang et al., 2003). The active metabolite 
of VD, 1,25(OH)2D3, which is known as calcitriol, has anti­
proliferative effects, can activate apoptotic pathways, and 
can inhibit angiogenesis (Deeb et al., 2007). In the hemato­
poietic system, numerous studies on AML blasts, leukemic 
cell lines, and primary myeloid precursors showed that VD 
induces cell differentiation into monocytes (Abe et al., 1981; 
Koeffler et al., 1984; Hmama et al., 1999; Bastie et al., 2004; 
Ji and Studzinski, 2004; Gemelli et al., 2008; Hughes et al., 
2009). Encouraging clinical trials have suggested that VD 
could be effective as a differentiating agent in the treatment 
of AML and myelodysplastic syndrome (MDS), but hypercal­
cemia has limited its use (Ferrero et al., 2004; Srivastava and 
Ambrus, 2004; Deeb et al., 2007).
Iron (Fe) is required as a cofactor for several critical cellu­
lar enzymes involved in energy metabolism and cell prolifera­
tion and is therefore essential for all living cells. Iron exists in 
two oxidation states, the ferrous (Fe2+) and the ferric (Fe3+) 
forms, which participate to the generation of reactive oxygen 
species (ROS) through the Fenton reaction. In this process, 
free cytosolic iron generates hydroxide anions and hydroxyl 
radicals from hydrogen peroxide (Fe2+ + H202↔Fe3+ +   
OH + OH•; Fenton et al., 1964) which can lead to cellular 
damages  (Davies,  2005).  Therefore,  iron  chelators  have   
been proposed to be anti­oxidant agents (Kalyanaraman, 
2007). However, iron chelators have also been shown to   
induce the generation of ROS under specific conditions 
(Chaston et al., 2004).
The transferrin receptor (CD71/TfR1) is an evolution­
arily conserved receptor that is essential for the uptake of   
iron in mammalian cells (Trowbridge and Shackelford, 1986;   
FLT3, or KIT mutations) and gene alterations/point mu­
tations in transcription factors or transcriptional coactivators 
(e.g., CEBP and NPM1) that affect differentiation (Fröhling 
et al., 2005; Roumier et al., 2006; Renneville et al., 2008). 
The most important transcription factors that have been impli­
cated in the myelomonocytic development are PU­1 for early 
myeloid commitment, C/EBP for granulocyte maturation, and 
vitamin D3 (VD) receptor (VDR) and MafB for monocyte­
macrophage differentiation (Sieweke and Graf, 1998; Friedman, 
2002; Mueller et al., 2002; Gemelli et al., 2008).
The potential of the currently available cytotoxic chemo­
therapies to treat AML might have reached its limit (Löwenberg 
et al., 1999; Ravandi et al., 2007). Moreover, the majority of 
patients with AML are 60 yr of age or older and, in this   
population, high­dose chemotherapy is associated with a   
high rate of morbidity and mortality. Although results of 
new therapeutic strategies have improved steadily in younger 
adults over the last 20 yr, there have been fewer improve­
ments in outcome among elderly patients (Löwenberg et al., 
2009). Based on the emerging knowledge of the biology of 
AML, new targeted therapeutic approaches need to be devel­
oped  to  interrupt  proliferation,  induce  apoptosis,  and/or 
override the differentiation block.
The current treatment modality for the induction of a 
terminal differentiation program in AML has only been 
achieved in acute promyelocytic leukemia (APL or AML3) 
by the use of differentiating agents combined with chemo­
therapy (Chen et al., 1994; Zhu et al., 2001; Wang and Chen, 
2008). In most of the cases, APLs are characterized by the 
translocation t(15;17), which encodes a fusion of the promy­
elocytic leukemia and retinoic acid receptor  proteins. The 
use of all­trans retinoic acid (ATRA) with chemotherapy was 
a major breakthrough in APL therapy. It has dramatically   
improved the prognosis from poor to a high cure rate (90% 
of patients; Wang and Chen, 2008). The use of arsenic triox­
ide (ATO) since the early 1990s further improved the clinical 
outcome of refractory or relapsed as well as newly diagnosed 
APL (Wang and Chen, 2008). Current evidences are now 
available to show that differentiation is not the only mecha­
nism explaining the therapeutic efficacy of ATRA or ATO 
in clearing APL, as retinoic acid also triggers growth arrest of 
leukemia initiating cells (Nasr et al., 2008).
different iron deprivation treatments, in contrast to many genes (1,094) that are altered by the iron chelators DFO and DFX. Genes with an intensity >50 and a  
p-value <0.001 were considered relevant. (b) Fold change variations of gene expression in differentiated cells relative to untreated cells. A24 and the iron 
chelators up-regulated monocyte/macrophage-specific genes and down-regulated myelocyte-specific genes. Up-regulation is represented on the positive 
scale, and down-regulation is indicated on the negative scale. (c) Fold increase of CD14 and CD11b expression after flow cytometry (mean fluorescence 
intensity [MFI] relative to untreated cells) in HL60 cell line treated with 10 µg/ml A24, 5 µM DFO, or 3 µM DFX for 72 h (mean ± SEM, n = 3). (d) Fold  
increase of CD14 and CD11b expression evaluated by flow cytometry (MFI relative to untreated cells) in U937 (white), THP1 (dark gray), OCI-AML3 (black), 
and NB4 (light gray) cell lines treated with 10 µg/ml A24, 5 µM DFO, or 3 µM DFX for 72 h (mean ± SEM, n = 3). (e) MGG-stained cytospins of HL60 cells 
treated with 250 nM VD, 10 µg/ml A24, 5 µM DFO, or 3 µM DFX for 72 h. The control cells show an immature myeloblastic phenotype: a high nucleus- 
to-cytoplasm ratio, a hyperbasophilic cytoplasm, and numerous azurophilic granules. The A24- or iron chelator–treated cells show a decrease in the  
nucleus-to-cytoplasm ratio, the loss of granules, and cytoplasmic basophilia and irregular cytoplasmic contours, all typical of mature monocytes. Bars,  
10 µm. Representative photos of three independent experiments are shown. (f) FACS analysis of CD14 expression in HL60 cells treated with A24 (green 
line), DFO, and DFX (blue lines) in the presence or absence of 5 µM FeCl3 (gray line) for 72 h. The filled histograms represent staining with the isotype con-
trol antibody. One representative experiment of three experiments is shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Lim et al., 1987; Daniels et al., 2006b). Cancer cells over­
express TfR1 and are more sensitive to iron depletion than 
their normal counterparts, most probably because of their 
high proliferative capacities (Faulk et al., 1980; Gatter et al., 
1983). TfR1 is a validated target for anti­cancer therapy using 
both mAbs and drug­conjugated transferrin (Trowbridge and 
Domingo, 1981; Daniels et al., 2006a). We have previously 
characterized an anti­TfR1 antibody (A24) that exhibits   
potential activity as a therapeutic anti­cancer agent (Moura   
et  al.,  2001).  A24  specifically  binds  to  TfR1high  cells,   
competes with iron­loaded transferrin (Fe­Tf) for receptor   
binding, and impairs receptor recycling, thereby drastically 
impairing iron uptake (Moura et al., 2004; Lepelletier et al., 
2007; Callens et al., 2008). Iron chelators have also been pro­
posed for several years as an alternative anti­cancer therapy 
and effectively induce cell growth arrest and apoptosis in   
cancer cells in vitro and in vivo (Richardson et al., 1994, 
2009; Le and Richardson, 2004; Whitnall et al., 2006).
Figure 2.  Iron deprivation inhibits proliferation and induces differentiation of AML blasts. (a) Fresh AML blasts or HL60 cells were cultured  
with increasing concentrations of A24 (0–20 µg/ml), DFO (0–50 µM), DFX (0–10 µM), or VP16 (0–100 ng/ml) for 72 h, followed by a 16-h period of  
[3H]-thymidine incorporation. Thymidine incorporation (percentage over the control) was plotted as the mean ± SEM of grouped M0/M1/M2 (n = 6)  
or M4/M5 (n = 9) subtypes patients. Cell proliferation for each patient was measured in triplicate. (b) HL60 cells were cultured in the presence or absence 
of 10 µg/ml A24 or 5 µM DFO for 72 h. Early and late apoptosis was evaluated by flow cytometry using annexin V–FITC/PI labeling (mean ± SEM, n = 3).  
*, P < 0.05; **, P < 0.01; ***, P < 0.001. (c) CD14 and CD11b expression in blasts from AML patients treated with A24 and DFO for 72 h. The expression of 
the differentiation markers was normalized by calculating the fold increase of the MFI relative to the control cells. The filled symbols represent the  
M0/M1/M2 AML subtypes, and the M4/M5 subtypes are empty symbols. One representative experiment of three is presented for each patient. The mean 
(horizontal bars) of the eight patients is shown.JEM VOL. 207, April 12, 2010 
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Induction  of  cell  surface  markers  in  treated  cells  was   
accompanied by the characteristic cytological modifications 
of monocytes, i.e., cytoplasm enlargement and loss of both 
cytoplasmic basophilia and azurophilic granules (Fig. 1 e and 
Fig. S1 c). Moreover, HL60 differentiated cells acquired 
functional properties of monocytes such as esterase activity 
(Fig. S1 d).
Supplementation of cultures with an excess of soluble iron 
abrogated expression of differentiation markers induced by 
iron deprivation (Fig. 1 f) but not by ATRA and VD (Fig. S2), 
confirming the role of iron availability in AML cell differ­
entiation. We next investigated whether primary cells from 
AML patients could also be sensitive to iron deprivation 
therapy. Fresh AML blasts from different AML subtypes 
(categorized  according  to  the  French­American­British 
[FAB] classification system [Bennett et al., 1976]) were iso­
lated at the time of diagnosis (Table S2, complete list of 
AML subtypes and biological parameters for the patients 
used in this study) and were cultured in the presence of A24 
and DFO.  An  arrest  of  cell  proliferation  (Fig.  2  a)  and 
induction of apoptosis (Fig. 2 b) were observed concomi­
tantly to CD14 and CD11b expression (Fig. 2 c), indicating 
that, similar to cell lines, blasts from different AML sub­
types, even if heterogeneous in the oncogenic events lead­
ing  to  their  arrest  in  differentiation  (Löwenberg  et  al.,   
1999), are susceptible to differentiation therapy based on   
iron deprivation.
Targeting of iron homeostasis induces primary progenitor 
differentiation toward the monocyte lineage
To verify if iron homeostasis plays a role in the differentia­
tion of primary granulocytes and monocytes, we tested the 
effect of iron deprivation on hematopoietic cord blood pro­
genitors. Iron deprivation agents did not change the total 
number of colonies derived from CD34+ cells in methylcel­
lulose plates (unpublished data). However, treatment with 
the iron chelators resulted in an increased number of bipo­
tent CFU­GM colonies (Fig. 3 a) and enhanced the ratio of 
CFU­M to the detriment of CFU­G colonies (Fig. 3 b), 
suggesting that chelating iron from hematopoietic precur­
sors induces commitment toward the monocyte over the 
granulocyte lineage. As expected, because iron is necessary 
for hemoglobin synthesis (Adamson, 1994) the number of 
CFU­E colonies was reduced by all the iron deprivation 
agents (Fig. 3 c).
When differentiation of CD34+ cord blood progenitors 
into granulocytes was induced in liquid cultures (Fig. S3), 
>65% of cells were polymorphonuclear cells after 18 d. 
We therefore added A24 or iron chelators to these granu­
locyte­oriented cell cultures every 3 d, at concentrations 
which  did  not  induce  cell  toxicity  (unpublished  data).   
Under these conditions, iron deprivation did not affect cord 
blood cell proliferation (Fig. 3 d) but rather enhanced their   
commitment toward the monocyte lineage because there   
was a consistent up­regulation of genes coding for tran­
scription factors specific for the monocyte lineage, such as 
The  molecular  mechanisms  underlying  the  anti­tumor 
effect of iron­chelating therapeutic approaches still need to 
be fully elucidated (Napier et al., 2005; Fu and Richardson, 
2007). We aimed to characterize these mechanisms and to 
validate their potential value in AML therapy. In this paper, 
we show in vivo, in vitro, and ex vivo that targeting iron   
homeostasis induces blast differentiation toward the mono­
cyte lineage, which is dependent on the modulation of ROS 
levels and the activation of the MAPK pathway. Importantly, 
iron deprivation induces VDR gene expression and VDR 
phosphorylation, providing the rationale for the combination 
of iron chelation and VD therapies. The synergistic effect of 
this association amplified the activation of the MAPK–JNK 
pathway and VDR­targeted genes. Finally, we provide data, in 
the form of a case report, showing the efficacy of this combina­
tion in the induction of tumor cell differentiation in an AML 
patient. This study provides the proof of concept for the use of 
combination of iron chelators and VD in AML therapy.
RESULTS
Targeting of iron homeostasis induces AML cell differentiation
To gain new insights in the molecular mechanisms in­
volved in the anti­tumor activity of iron­chelating therapeu­
tic approaches, we sought to identify genes that are affected 
both by iron chelators (deferoxamine [DFO] and deferasirox 
[DFX]) and by impairment of Fe­Tf uptake (using the anti­
TfR1 mAb A24 [Moura et al., 2004; Lepelletier et al., 2007; 
Callens et al., 2008]). Indeed, A24 targets TfR1 (the major 
receptor involved in the iron entry in the cells), whereas iron 
chelators can also capture other bivalent ions (e.g. Mn2+, 
Cu2+, or Zn2+) which could modulate genes irrelevant to 
iron homeostasis. Thus, identification of overlapping genes 
allows us to avoid selecting off­target genes. We focused our 
first studies in a cell line (HL60) to avoid heterogeneity in the 
data related to the multiple genetic events that have been   
implicated in AML oncogenesis. An analysis of the collected 
data revealed that 105 genes were similarly modulated by the 
three iron deprivation agents (Fig. 1 a and Table S1). Among 
these genes, several were related to cell differentiation. Markers 
of monocytes or activated macrophages were up­regulated, 
whereas granulocyte markers were down­regulated (Fig. 1 b). 
These results were confirmed by real­time quantitative PCR 
and extended to other AML cell lines from different AML 
subtypes (Fig. S1 a).
We further tested the ability of iron deprivation to override 
the block of cell differentiation observed in AML cells. We 
followed the expression of CD14 and CD11b monocyte cell 
surface markers (Kansas et al., 1990) after iron deprivation 
induced by treatment with A24, DFO, or DFX. Expression 
of both markers was induced by iron deprivation, suggesting 
that cells underwent differentiation (Fig. 1 c) similar to VD­
treated cells (Fig. S1 b). Up­regulation of monocyte cell sur­
face markers, initially detected in myeloblastic cells (HL60), 
was  also  observed  in  cell  lines  from  myelo/monoblastic 
(OCI AML­3), monoblastic (U937 and THP1), and pro­
myelocytic (NB4) origin (Fig. 1 d).736 Iron chelation drives AML differentiation | Callens et al.
Figure 3.  Iron deprivation induces the differentiation of primary progenitors into monocytes. CD34+ cord blood progenitors were plated in 
methylcellulose containing a cocktail of cytokines (Epo, SCF, IL-3, G-CSF, and GM-CSF) in the presence or absence of 10 µg/ml A24, 5 µM DFO, or 3 µM 
DFX. After 14 d, colonies of each lineage were counted (mean ± SEM, n = 3). (a and b) Variations of colonies are represented as the fold increase of  
CFU-GM (a) or the ratio of CFU-M/CFU-G (b). (c) Fold decrease of CFU-E. (d) Cell numbers and viability measured by Trypan blue dye exclusion during 
culture. One representative experiment of three is shown. All counts were performed in triplicates. (e) After 48 h of culture, the mRNA expression of 
HOXA10, EGR1, and MAFB was quantified by quantitative RT-PCR and normalized to the expression of GAPDH (mean ± SEM, n = 3). (f) Representative 
photos taken at the end of culture (day 18) are shown. Polymorphonuclear neutrophils are present in the majority of the control cultures, whereas mono-
cytes and macrophages are predominantly present under iron deprivation conditions. The histograms represent the percentage of each leukocyte popula-
tion from MGG-colored cytospins at day 18 (mean ± SEM, three independent counts of 100 cells each). Bars, 10 µm. *, P < 0.05; **, P < 0.01; ***, P < 0.001.JEM VOL. 207, April 12, 2010 
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HOXA10, EGR1, and MafB (Sieweke et al., 1996; Kelly 
and Gilliland, 2002; Taghon et al., 2002; Friedman, 2007; 
Fig. 3 e). Cytological examination confirmed that the mono­
cyte cell number was higher in iron­poor cultures (Fig. 3 f). 
Therefore,  in  hematopoiesis,  iron  availability  could  be   
an important factor in determining whether a hematopoi­
etic progenitor cell differentiates toward a monocyte or   
a granulocyte.
Figure 4.  Modulation of ROS levels controls monocyte differentiation in AML cells. (a) Representative flow cytometry analysis showing ROS 
production by NB4 cells. Cells were stained for 30 min at 37°C with 0.5 µM DHR123 or 1 µM DHE and further treated with 3 µM DFX (continuous line) or 
not (filled histograms) for 90 min. One representative experiment of three is presented. (b) ROS production in AML cell lines (HL60 and OCI-AML3 cells) is 
dose dependent. Cells were labeled with DHR123 (as described in a) and treated with 3 µM DFX (continuous line) or 0.3 µM DFX (dashed line) for 90 min 
or not (filled histograms). One representative experiment of three is presented. (c) Time-dependent production of ROS. NB4 cells were treated with 3 µM 
DFX for 90 min (continuous line) or 150 min (dashed line). ROS production was evaluated by flow cytometry. One representative experiment of three is 
presented. (d) Representative flow cytometry data showing specificity of the ROS production by NB4 cells. Cells were stained for 30 min at 37°C with  
0.5 µM DHR123 and further treated with 3 µM DFO. Abrogated ROS detection is shown in cell cultures where DFO was added in the presence of the anti-
oxidant NAC (dashed line) as compared with control untreated cells (filled histogram). One representative experiment of three is presented. (e) CD14  
expression (fold change) in HL60 cells treated with 10 µg/ml A24 and 5 µM DFO in the presence or absence of the anti-oxidant agents (NAC and PDTC)  
for 72 h (mean ± SEM, n = 3). (f) CD14 expression in OCI-AML3 and NB4 cells treated with DFO in the presence or in the absence of the anti-oxidant 
agent NAC for 72 h (mean ± SEM, n = 3). ***, P < 0.001.738 Iron chelation drives AML differentiation | Callens et al.
et al., 2009). By comparing the pattern of genes induced by 
VD and by iron­chelating agents in a nonsupervised tran­
scriptome analysis, we found a high similarity between the 
differentially expressed genes; of the 105 genes that were 
modulated by iron deprivation, 30 were also modulated by 
treatment with VD (Fig. 6 a and Table S3). Both VD and the 
iron­chelating  agents  up­regulated  monocyte  markers  and 
down­regulated neutrophil markers (Fig. 6 b). Moreover, in 
gene chips (Fig. 6 c) and real­time quantitative PCR (Fig. 6 d) 
analysis, transcription of the c-Jun gene was induced by both 
VD and iron deprivation. Transcripts coding for c-Fos were 
also up­regulated by both treatments (Fig. 6 d), suggesting 
the involvement of the JNK pathway. Similar results were 
observed in cell lines from different AML subtypes (Fig. 6 e). 
To further address the role of JNK, cells were transfected 
with micro RNA (miRNA) constructs specific for different 
members of the JNK pathway (namely JNK1, JNK2, and   
c­Jun; Fig. S5, a–c). miRNA–mediated silencing of c­Jun, 
JNK1,  and  JNK2  markedly  abrogated  cell  differentiation   
induced by iron deprivation agents (Fig. 6 f). Overexpression 
of each one of the two JNK proteins revealed that JNK1 was 
the  most  effective  to  induce  cell  differentiation  of  AML   
cells (Fig. 6 g).
Given the high similarities shared between VD and iron 
deprivation agents to induce cell differentiation, we investi­
gated whether iron deprivation of cells could induce VDR 
signaling (Wang et al., 2003; Himes et al., 2006). As ob­
served for its cognate ligand VD, VDR expression was in­
duced in cells treated by iron­chelating agents (Fig. 6 h). 
The addition of iron chelators to cells starved of growth 
factors readily induced the VDR phosphorylation (Fig. 6 i) 
involved in the control of VDR activity (Jurutka et al., 
1996). Altogether, these results indicate that iron­chelating 
agents are able to induce cell differentiation through the 
activation of JNK pathway. Iron deprivation also potenti­
ates VDR signaling pathway through VDR expression and 
VDR phosphorylation.
VD synergizes with iron deprivation agents through the 
activation of the Jun pathway to induce cellular differentiation
Treatment of cells with both iron chelators and VD drasti­
cally  increased  the  up­regulation  of  monocyte  markers 
CD11b and CD14 (Fig. 7 a). We consequently investigated 
whether the combination of iron­chelating agents (as the 
iron chelator DFO and the anti­TfR1 A24) and VD had a 
synergistic effect. Applying the combination index (CI) iso­
bologram method (Chou and Talalay, 1984), we evaluated 
interactions between DFO and VD, or A24 and VD (Figs. S6, 
a–d). At the concentration inducing 50% of CD14+ cells, CI 
values for the combination of DFO and VD, or A24 and 
VD, were <1 (0.87 and 0.89, respectively), indicating a syn­
ergistic interaction. Both combinations were accompanied 
by morphological changes in the treated cells (Fig. 7 b) and 
by higher expression of VDR (Fig. 7 c). The physiological 
relevance of increased VDR gene expression was demon­
strated by the robust increase in the transcription of its 
Iron deprivation–induced cell differentiation is dependent 
on the modulation of ROS levels
ROS production is highly dependent on the intracellular   
labile iron pool (LIP). Therefore, to investigate whether 
iron­chelating agents modulate ROS levels in AML cells,   
we used a metallo­sensor fluorescent probe (calcein) for LIP 
measurements (Espósito et al., 2002) and dihydrorhodamine 
123 (DHR123) as an indicator of the degree of general oxi­
dative stress or dihydroethidium (DHE) to monitor cellular 
superoxide  production  (Owusu­Ansah  et  al.,  2008).  As 
expected, previous addition of iron deprivation agents de­
creased LIP levels in AML cells and DFX was the fastest and 
most efficient compound (Fig. S4, a–c). Iron deprivation of 
cells by DFX (the most permeant chelators) was readily ac­
companied by ROS formation (Fig. 4 a), which was found to 
be concentration (Fig. 4 b) and time (Fig. 4 c) dependent. 
We further confirmed the specificity of ROS detection by 
preincubating  iron­deprived  cells  with  the  anti­oxidant   
N­acetyl­l­cysteine (NAC; Fig. 4 d).
Iron chelators had opposite effects depending on whether 
AML cells were treated during short (1–3 h; Fig. 4, a–d) or 
long (16–18 h; Fig. S4, d–f) periods of time. In addition, in 
HL60­cultured cells treated for 16–18 h with iron chelators, 
the H2O2­mediated generation of ROS was abrogated in a 
dose­dependent manner (Fig. S4, d and e), whereas ATO in­
duced a sustained production of ROS in NB4 cells (Fig. S4 f).
To further clarify which of the pro­ or anti­oxidant ef­
fects of iron chelators was implicated in monocyte differenti­
ation, iron­deprived AML cells were treated with or without 
the anti­oxidants NAC or pyrrolidine dithiocarbamate (PDTC). 
Anti­oxidant prevented the increase in CD14 mediated by 
iron deprivation differentiation, suggesting that cell differen­
tiation is dependent on the increased ROS levels induced 
during the early course of cellular iron deprivation (Fig. 4, 
e and f). Thus, iron­depriving agents control cell differen­
tiation through modulation of ROS levels.
Cell differentiation induced by iron deprivation is dependent 
on the activation of the MAPK pathway
MAPKs are serine/threonine protein kinases crucial to sev­
eral biological responses including stress responses to ROS 
(Whitmarsh and Davis, 1999). The addition of the specific 
inhibitors of ERK, JNK, and p38 MAPK signaling pathways 
(which characterize the three MAPK families) abrogated cell 
differentiation induced by iron deprivation agents (Fig. 5 a). 
The iron­chelating agents induced the phosphorylation of 
ERK, p38, and JNK (Fig. 5 b). However, only inhibitors of 
JNK and p38, but not of ERK, prevented iron deprivation–
induced apoptosis (Fig. 5 c).
Iron deprivation–induced cell differentiation shares high 
similarity with that induced by VD
VD  can  induce  monocyte/macrophage  differentiation  of 
both primary cells and myeloid leukemia cell lines (Abe et al., 
1981; Koeffler et al., 1984; Hmama et al., 1999; Bastie et al., 
2004; Ji and Studzinski, 2004; Gemelli et al., 2008; Hughes JEM VOL. 207, April 12, 2010 
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iron chelators was specific to VDR signaling because iron 
chelators did not potentiate the ability of ATRA to promote 
cell differentiation in HL60 cells (Fig. S7). Finally, the effi­
cacy of the combined therapy was validated ex vivo in pri­
mary cells from AML patients (Fig. 7 g).
downstream target genes, cathelicidin (1,000­fold increase) 
and  CYP24A  (6,000­fold  increase;  Fig.  7  d),  and  c-Fos  
and  c-Jun  (Fig.  7  e).  Moreover,  the  phosphorylation  of 
JNK increased in response to treatment with both VD and 
iron deprivation (Fig. 7 f). The combined effect of VD and 
Figure 5.  Cell differentiation and apoptosis are controlled by MAPK activation. (a) CD14 expression on HL60 cells cultured in the presence or 
absence of A24 (green) or DFO (blue) and treated with a JNK inhibitor (SP600125) at 2.4 or 12 µM, with a p38 inhibitor (SB203580) or an ERK inhibitor 
(PD98059) at 3 or 10 µM, or mock treated for 72 h. Filled histograms represent staining with the isotype control antibody. One representative experiment 
of three experiments is shown. (b) Serum-starved HL60 cells were incubated with 10 µg/ml A24 or 3 µM DFO for 30 min at 37°C. Whole cell extracts were 
analyzed by immunoblotting, demonstrating the phosphorylation of JNK (p-JNK), ERK (p-ERK), and p38 (p-p38). One representative experiment of three 
experiments is shown. HSC70 and ERK were used as equal loading controls. (c) Histograms representing early and late apoptosis/necrosis using flow  
cytometry with annexin V–FITC/PI labeling. HL60 cells were cultured for 72 h in the presence or absence of 10 µg/ml A24 or 5 µM DFO and treated  
with 2 or 6 µM JNK inhibitor (SP600125 [SP]), 0.5 or 1 µM p38 inhibitor (SB203580 [SB]), 3 or 10 µM ERK inhibitor (PD98059 [PD]), or mock treated  
(mean ± SEM, n = 3). *, P < 0.05; ***, P < 0.001.740 Iron chelation drives AML differentiation | Callens et al.
Figure 6.  Cellular differentiation induced by iron deprivation is dependent on the activation of the JNK and VDR signaling pathways.  
(a) Hierarchical gene clustering by unsupervised microarray analysis in HL60 cells treated with 250 nM VD or iron chelating agents (A24, 10 µg/ml; DFO,  
5 µM or DFX, 3 µM). Only genes with a fold change >4 and a p-value <1015 are shown (left). A Venn diagram is shown, demonstrating that among the  
105 genes that were specifically induced by iron deprivation, 30 were modified by treatment with VD (right). (b) Histograms representing the variation of  JEM VOL. 207, April 12, 2010 
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expression (fold change relative to untreated cells) of genes found in mature monocytes (up-regulated) or neutrophils (down-regulated) that were  
previously modified by A24 and the iron chelators. These genes are similarly regulated by VD treatment. Up-regulation of gene transcription is represented 
on the positive scale, and down-regulation is shown on the negative scale. (c) Genechip fold change in c-Jun expression after treatment with VD or iron  
deprivation. (d) c-Fos and c-Jun mRNA levels evaluated by quantitative RT-PCR and normalized to GAPDH mRNA in HL60 cells treated for 48 h with the  
indicated agents (VD, 250 nM; A24, 10 µg/ml; DFO, 5 µM or DFX, 3 µM; mean ± SEM, n = 4). (e) c-Jun mRNA level evaluated by quantitative RT-PCR and 
normalized to GAPDH mRNA in U937, OCI-AML3, NB4, and THP1 cell lines treated for 48 h with the indicated agents (VD, 250 nM; A24 10 µg/ml; DFO, 5 µM 
or DFX, 3 µM; mean ± SEM, n = 4). (f) Fold increase of CD14 expression in HL60 cells transfected with the indicated miRNA constructs: scrambled control 
miRNA, miRNA-C-Jun, miRNA-JNK1, or miRNA-JNK2. 48 h later, each transfected cells were treated with 5 µM DFO to induce cell differentiation. CD14 
expression was evaluated by flow cytometry gating on cells on the basis of their GFP expression 72 h after transfection (mean ± SEM, n = 3). (g) Percentage 
of differentiated cells induced in HL60 treated for 72 h with DFO or transfected with JNK1-GFP and JNK2-GFP expression plasmids or mock electroporated. 
CD14 expression was evaluated 72 h after treatments (mean ± SEM, n = 3). (h) VDR mRNA level evaluated by quantitative RT-PCR and normalized to 
GAPDH mRNA in HL60 cells treated for 48 h with the indicated agents (A24, 10 µg/ml or DFO, 5 µM; mean ± SEM, n = 4). *, P < 0.05; **, P < 0.01; 
***, P < 0.001. (i) Serum-starved HL60 and U937 cells were incubated with 0.5 µM H2O2, 10 µg/ml A24, or 3 µM DFO for 10 min at 37°C. Phosphorylation of 
VDR (P-VDR) in whole cell extracts was analyzed by immunoblotting. VDR was used as loading control. One representative experiment of three is shown.
 
In vivo efficacy of combined iron homeostasis and VD 
treatment through the activation of the MAPK–JNK pathway
Based on these observations, we postulated that the combina­
tion of iron deprivation and VD could intensify their anti­
leukemic properties. Therefore, the efficacy of differentiation 
therapy was further evaluated in vivo in a mouse tumor xe­
nograft model. A single dose of A24 completely inhibited the 
growth  of  HL60  transplanted  tumors,  whereas  treatment 
with DFO increased survival and decreased the tumor size 
(Fig. 8, a and b). Using this model, we did not observe a sig­
nificant reduction in tumor growth for mice treated with VD 
alone (Fig. 8 c). However, the combination of VD with DFO 
significantly reduced tumor growth (Fig. 8 d). The parameters 
of serum iron homeostasis, such as serum transferrin and   
ferritin levels, were significantly modified in the treated mice, 
which is an indication of effective iron deprivation (Fig. 8 e). 
The reduced tumor growth was associated with tumor cell 
apoptosis, which are features of cellular differentiation and 
MAPK phosphorylation (ERK and JNK; Fig. 8 f). In mice 
xenografted with OCI­AML3 cells, DFO greatly improved 
event­free survival (Fig. S8 a). There was no significant dif­
ference  in  event­free  survival  between  mice  treated  with 
DFO and DFO + VD. However, a significant reduction in 
tumor growth was observed only in mice that received the 
DFO + VD association, although the DFO­treated mice pre­
sented reduction in tumor growth compared with control 
which did not reach significance (Fig. S8 b).
Case report
Because both iron chelators and VD analogues are safe drugs 
currently used as therapies in the treatment of diseases other 
than leukemia, their effectiveness in one AML patient was 
evaluated. A 69­yr­old man had a recent transformation of 
MDS into AML. After high­dose chemotherapy, the patient 
remained in non­blastic aplasia. 7 mo after the diagnosis, blasts 
reappeared in the blood. High­dose chemotherapy was denied, 
and treatment with an iron chelator (1 g/d DFX) and 25­
hydroxycholecalciferol (4,000 IU/d) was initiated.
Blast counts, although progressing before therapy, were 
decreased upon iron chelation and vitamin D therapy, and 
pancytopenia was partially reversed, accompanied by an   
increase in monocyte numbers (Fig. 9 a) without inducing 
hypercalcemia (Fig. 9 b). Importantly, May Grünwald Giemsa 
(MGG) blood smears revealed an increased number of differ­
entiating cells toward the monocyte lineage, suggesting that 
they were derived from the blast pool (Fig. 9 c). Cell sorting 
(Fig. 9 d), followed by fluorescent in situ hybridization analy­
sis, showed that the original trisomy 8 found in the blasts of 
the patient (Fig. 9 e) was segregated with the sorted mature 
monocyte population but not with lymphocytes or NK cells 
(Fig. 9 f), confirming that the circulating monocytes were 
derived from the blast pool. In addition, the patient’s quality 
of life was improved because red cell and platelet transfusion 
needs were decreased. Furthermore, the patient could con­
trol several microbial infections that otherwise would have 
been life threatening, suggesting that the patient’s immune 
status was partially restored. These data underscore the differ­
entiating efficiency of combined therapy in human AML.
DISCUSSION
We show in this paper that iron homeostasis plays a key role 
in the control of myeloid differentiation in both normal   
and pathological situations. Iron deprivation of undifferenti­
ated myeloid cells, either through iron chelation or through 
blocking of iron uptake, induced transcription of several 
markers of the monocyte/macrophage lineage. At the same 
time, iron deprivation shunted progenitors away from the gran­
ulocytic lineage by dampening the transcription of granulocyte­
specific markers. Morphological, phenotypic, and functional 
analyses confirmed and extended these observations. Not only 
did iron deprivation induce primary progenitor commitment 
toward the monocyte lineage, it also reestablished differentia­
tion in AML blasts/cell lines.
Recent cumulated data in the literature have shown that 
ROS can modulate the activation of signal transduction path­
ways involved in several cellular functions such as cell prolif­
eration and differentiation (Sattler et al., 1999). Specifically, 
in the mammalian hematopoietic system, it has been recently 
reported that hematopoietic stem cells produce low levels of 
ROS, which are increased in common myeloid progenitors. 
Modulation in ROS levels seems to be important in the control 
of myeloid precursor differentiation (Tothova et al., 2007). 742 Iron chelation drives AML differentiation | Callens et al.
Figure 7.  VD synergizes with iron deprivation agents to activate the Jun pathway and induce cellular differentiation. (a) Flow cytometric 
analysis of CD14 and CD11b expression on HL60 cells treated with 10 µg/ml A24 (green line) or 5 µM DFO (blue line), with 250 nM VD (gray lines) or a 
combination of VD and iron-chelating agents (black lines) for 72 h. The filled histograms represent staining with the isotype control antibody. One  
representative experiment of three is shown. (b) HL60 cells were incubated with 10 µg/ml A24 or 3 µM DFO and treated with 250 nM VD or mock treated JEM VOL. 207, April 12, 2010 
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for 72 h. Cytospins for the treated cells were stained with MGG. Monocyte differentiation is observed with the loss of granulation and basophilia, vacuole 
appearance, and cytoplasm enlargement. Bars, 10 µM. Representative photos of three independent experiments are shown. (c) The VDR mRNA level,  
evaluated by quantitative RT-PCR and normalized to GAPDH in HL60 cells treated for 6 h with the indicated agents (A24, 10 µg/ml; DFO, 5 µM; or VD,  
250 nM; mean ± SEM, n = 4). (d) The mRNA level of Cathelicidin and CYP24A, evaluated by quantitative RT-PCR and normalized to GAPDH, in HL60 cells 
treated for 6 h with the indicated agents (A24, 10 µg/ml; DFO, 5 µM; or VD, 250 nM; mean ± SEM, n = 4). (e) The mRNA level of c-Fos and c-Jun genes, 
evaluated by quantitative RT-PCR and normalized to GAPDH, in HL60 cells treated for 16 h with A24, DFO, and VD as described in c (mean ± SEM, n = 4). 
(f) Serum-starved HL60 cells were incubated with 10 µg/ml A24 or 3 µM DFO and treated with 250 nM VD or mock treated for 30 min at 37°C. Whole cell 
extracts from the treated cells were analyzed by immunoblotting, demonstrating the increased phosphorylation of JNK when VD is combined with A24 or 
DFO. HSC70 and total ERK were used as loading controls. One representative experiment of three is shown. (g) Fold increase of CD14 and CD11b expres-
sion analyzed by flow cytometry (MFI relative to untreated cells) in primary blasts from two AML patients, identified as SL4 (AML2 FAB subtype) and SL12 
(AML0 FAB subtype). Cells were treated with 10 µg/ml A24, 5 µM DFO, 3 µM DFX, or 250 nM VD or their association as indicated for 72 h (mean ± SEM,  
n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
 
This process seems to be conserved throughout evolution be­
cause  Drosophila  melanogaster  multipotent  hematopoietic   
progenitors display increased levels of ROS which are down­
regulated during differentiation (Owusu­Ansah and Banerjee, 
2009). However, factors controlling ROS production in 
myeloid progenitors are not well known. We show in this 
paper that intracellular LIP could be one of these factors   
playing a critical role in controlling ROS levels and, thus, 
cell differentiation in the hematopoietic system.
Scavenging ROS from Drosophila melanogaster hemato­
poietic progenitors delays mature blood cell differentiation, 
which is dependent on the MAPK JNK (Owusu­Ansah and 
Banerjee, 2009). In this paper, we show that both genetic   
and pharmacological inactivation of the MAPK–JNK path­
way  inhibited  iron  deprivation­induced  cell  differentia­
tion. Furthermore, pharmacological blocking of ROS abrogated 
iron deprivation–induced cell differentiation, suggesting that 
ROS and MAPK pathways are linked, most probably by the 
direct effect of ROS on MAPK activation (Martindale and 
Holbrook, 2002). Signal transduction cascades of MAPK 
pathways frequently converge to amplify signaling (Johnson 
and Lapadat, 2002; Lopez­Bergami et al., 2007). Inhibition 
of ERK and p38 pathways prevented cell differentiation in­
duced by iron deprivation. Blocking of the ERK pathway 
did not block apoptosis induced by iron chelators, suggesting 
that redundant and nonredundant MAPK signaling pathways 
are involved in the control of AML cell differentiation and 
apoptosis. In agreement, it has been previously shown that 
the MAPK–ERK pathway is constitutively active in AML 
cells and in G­CSF–mobilized CD34+ precursors and inhibi­
tion of ERK pathway promotes growth arrest rather than 
apoptosis (Ricciardi et al., 2005). Combining iron chela­
tion therapy with other MAPK/ERK activators, such as 
G­CSF, remains to be evaluated. Altogether those data 
suggest that cross talk between MAPK pathways could co­
operate to regulate AML cell differentiation and its sensitivity 
to cytotoxic agents.
In the majority of the experiments presented in this   
paper, TfR1 targeting by A24 mimicked the effect of iron 
chelators at least in in vitro and ex vivo settings. Because each 
of the iron­chelating agents has its own chemical/biochemi­
cal characteristics (such as the structure or cell­permeant 
properties of the different iron chelators and cell targeting 
specificity of the monoclonal antibody) and pharmacological 
properties (such as the kinetics and half­life), the intensity of 
the response varied among them. For example, in tumor   
xenograft experiments, A24 mAb totally inhibited tumor en­
graftment, whereas iron chelators delayed the tumor growth, 
a difference probably involving additional effects of A24 such 
as antibody­dependent cellular cytotoxicity or complement­
dependent cytotoxicity. In addition, A24 could exert a spe­
cific target effect by inducing TfR1 down­regulation specifically 
on TfRhigh tumor cells (Moura et al., 2004; Lepelletier et al., 
2007; Callens et al., 2008), whereas iron chelators are more 
likely to induce TfR1 messenger RNA (mRNA) stability by 
posttranscriptional mechanisms.
The principal molecular mechanism drawn from the ex­
periments reported in this paper links the signaling pathways 
activated by iron deprivation and by VD. Gene expression 
studies showed a high similarity (30% common genes) be­
tween genes modulated by VD and the set of 105 genes   
targeted by iron deprivation. In addition, iron deprivation 
induced both VDR gene expression and VDR phosphoryla­
tion. The phosphorylation of VDR on serine 208 by casein 
kinase II has been shown to control activation of VDR gene 
transcription and VDR target genes expression (Jurutka et al., 
1996). Therefore, iron deprivation could induce, by itself, the 
activation of VDR signaling pathway. Furthermore, the com­
bination of iron deprivation agents and differentiating thera­
pies acted synergistically, increasing AML cell differentiation.
Altogether, our data identified a mechanism involving se­
quentially iron­deprivation, ROS production, and activation 
of MAPK pathways, further amplified by induction of VDR 
expression and phosphorylation, culminating in monocyte/
macrophage differentiation. Recent studies showed an un­
expected constitutive activation of Syk tyrosine kinase in AML 
blasts (Hahn et al., 2009). Gefitinib has been identified as a 
Syk tyrosine kinase inhibitor (Hahn et al., 2009) and reported 
to be a potent inducer of AML cell differentiation in preclini­
cal settings (Boehrer et al., 2008). These studies unveiled Syk 
as a previously unsuspected regulator of AML differentiation. 
Although the molecular pathways regulating the activation of 
Syk in AML cells remain unknown, a study by Agramonte­
Hevia et al. (2003) reported that VD­induced cell differentia­
tion down­regulated the high Syk activation observed in 
undifferentiated THP­1 cells. Therefore, down­modulation 744 Iron chelation drives AML differentiation | Callens et al.
Figure 8.  Anti-tumor effect of iron deprivation combined with VD in Nude mice. (a) Kaplan-Meier plot of the percentage of tumor-free mice 
among mice treated with vehicle (control), A24 (single intravenous dose of 40 mg/kg), and DF0 (20 mg 5×/wk) after subcutaneous xenograft with HL60 
cells (n = 4 in each group). The p-value was determined using the log-rank test. One representative experiment of three is shown. (b) Representative  
photographs of xenografted tumors from Fig. 5 a. Bars, 10 mm. (c) Tumor size (measured at day 25) in HL60 cells xenografted in Nude mice. Individual 
tumor sizes are plotted. The horizontal bars represent the mean of each group (n = 12 in the control group, n = 12 in VD group). One representative ex-
periment of three is shown. (d) Tumor size measured at day 25 in xenografted mice. Individual tumor sizes are plotted. The horizontal bars represent the 
mean of each group (n = 14 in the control group, n = 14 in the DFO group, and n = 12 in the DFO + VD group). (e) Serum ferritin and transferrin levels in 
xenografted mice. 25 d after the engraftment, the mice were euthanized, and serum was collected for biochemical analysis (mean ± SEM). (f) Sections of JEM VOL. 207, April 12, 2010 
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tumors from mice injected with vehicle, DFO, and DFO + VD were stained by HE, TUNEL, or labeled with CD11b-, p-ERK– or p-JNK–specific antibodies. The 
arrows indicate apoptosis. Representative photos of one experiment are shown. Data were quantified using Image J software. Bar, 50 µm. Histograms 
represent quantification of at least four different fields. One representative experiment is shown (mean ± SEM). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
 
of Syk activity downstream VDR activation could participate 
in cell differentiation induced by iron deprivation agents and 
it remains to be evaluated.
VD is known to induce myeloid progenitors to differen­
tiate into monocytes. In vitro and ex vivo experiments were 
promising, but in the first clinical trials in AML and MDS, 
only partial differentiation was obtained and clinical improve­
ments were modest (Deeb et al., 2007). In addition, symp­
tomatic hypercalcemia limited VD clinical application. Clinical 
trials using VD analogues, which do not promote hypercal­
cemia, did not improve patients’ prognosis (Koeffler et al., 
2005), suggesting that VDR stimulation alone is not suffi­
cient to promote clinical benefit. We show in this paper that 
iron deprivation could be a new therapeutic approach in 
AML, and likely in MDS, because it synergizes with VD (low 
dose). The combination of iron chelators and VD induced 
both pro­differentiating and antiproliferative effects in leuke­
mia cells from one AML patient, as described in this paper in 
the form of a case report. This association reduced the rate of 
blast proliferation and promoted blast differentiation toward 
monocytes without emergence of hypercalcemia. The pa­
tient developed multiple infectious episodes, which were 
greatly reduced after the initiation of VD and iron chelation 
combined therapy. In vitro experiments showed that, in ad­
dition to its role in monocyte differentiation, the associated 
therapy promoted expression of genes related to antimicro­
bial defense such as cathelicidin. Therefore, the early use of 
iron chelators in AML therapy, in addition to preventing re­
lapses and enhancing time to progression, could act at multi­
ple levels: by preventing red cell transfusion­derived secondary 
iron overload, by avoiding defective bone marrow reconsti­
tution after allogeneic HSCT, and also by improving patients’ 
immune status (Pullarkat et al., 2008; Pullarkat, 2009).
Because AML incidence increases with age and because 
the world population is growing older, we propose that the 
combined therapy would be particularly useful in elderly pa­
tients who are not eligible for high dose chemotherapy and 
bone marrow transplantation. This combined therapy could 
be also relevant in other diseases involving a deregulation of 
BM differentiation, such as MDS. Additional clinical studies 
are needed to validate its efficacy and determine in which   
patients it will be more beneficial.
MATERIALS AND METHODS
Clinical samples and cell lines. Peripheral blood cells were obtained from 
AML patients and healthy donors after obtaining their written informed 
consent (Table S2, additional information) and approval obtained by the 
Necker and Saint­Louis Hospitals Institutional ethic committees. Peripheral 
blood was collected at the initial diagnosis before the administration of treat­
ment. Mononuclear cells were separated by Ficoll­hypaque (PAA laboratories) 
density centrifugation and resuspended in IMDM (Invitrogen) supple­
mented with 15% FCS (Hyclone), 100 ng/ml stem cell factor (SCF), 10 ng/ml 
IL­3, and 25 ng/ml FLT3­L (all purchased from R&D Systems). Myelocytic 
(HL60 and OCI­AML3), monoblastic (THP1 and U937), and promyelo­
cytic (NB4) leukemia cell lines used in the present study were provided by 
J.M. Cayuela (Hôpital Saint­Louis, Paris, France) and P. Villarese (Hôpital 
Necker, Paris, France). Cells were cultured in RPMI­1640 medium (In­
vitrogen) supplemented with 5% FCS and antibiotics.
Cell treatment and proliferation assays. DFX was provided by Novartis. 
Etoposide (VP16), ATRA, DFO, 25­OH­VD, H2O2, FeCl3, NAC, and 
PDTC were purchased from Sigma­Aldrich. Calcein­AM, DHR123, and 
DHE were purchased from Invitrogen. The mAb A24 was produced and 
purified as described previously (Moura et al., 2001). The inhibitors of JNK 
(SP600125), ERK (PD98059), and p38 (SB203580) were obtained from 
Santa Cruz Biotechnology, Inc.
For proliferation assays, the HL60 cell line was resuspended in RPMI­
1640 medium with 5% FCS, whereas the patient blasts were resuspended in 
IMDM with 15% BIT 9500 (STEMCELL Technologies Inc.). The cells 
were plated in triplicate at 2.5 × 104 cells per well in 96­well tissue culture 
plates (Falcon) in 200 µl of culture medium. Proliferation was measured as 
described previously (Lepelletier et al., 2007).
Calcein assay for intracellular LIP. LIP was evaluated according to a 
previously described method (Espósito et al., 2002) with some modifica­
tions. In brief, cells were treated with 0.5 µM calcein­AM for 30 min at 
37°C. Before being subjected to flow cytometry analysis, cells were treated 
or not with an excess of cell­permeant iron chelators. The fluorescein chan­
nel was used to detect calcein fluorescence. The difference between calcein 
fluorescence before and after adding cell­permeant iron chelators indicated 
the relative amount of LIP (Espósito et al., 2002).
Measurement of intracellular ROS. Fluorescence analysis was used to 
determine the relative levels of ROS in response to various stimuli. ROS 
levels were detected by FACS analysis. Labeling with cell­permeant redox­
sensitive fluorochromes was performed for 30 min at 37°C in the presence 
of 1 µM DHE or 0.5 µM DHR123, both diluted in 0.5% BSA in HBSS   
solution (Invitrogen).
Overexpression and silencing of JNK1, JNK2, and c-Jun. For overex­
pression,  pEGFP­C3  (Takara  Bio  Inc.)  expression  vectors  containing   
cDNA encoding JNK1 or JNK2 between the HindIII/BamHI sites (pro­
vided  by  T.  Herdegen,  Institute  of  Pharmacology,  University  Hospital 
Schleswig­Holstein, Kiel, Germany) were used. These proteins were ex­
pressed as a GFP fusion protein under the control of human CMV im­
mediate early promoter.
For C-Jun, JNK1, and JNK2 gene silencing, artificial miRNA constructs 
were generated. Four sets of predesigned miR RNAi sequence oligonucle­
otides for each gene were obtained using BLOCK­iT miR RNAi Select 
(Invitrogen) and checked to ensure the designed sequences would not target 
other gene transcripts to avoid any off­target effects. These oligonucleotides 
were annealed and ligated into the pcDNA6.2­GW/EmGFP­miR vector 
according to the manufacturer’s instructions (Invitrogen) to express the   
pre­miRNA as an EmGFP fusion under the control of human CMV imme­
diate early promoter. The pcDNA 6.2­GW/EmGFP­miR–negative control 
plasmid contains a scrambled miRNA insert, which is predicted not to target 
any known vertebrate gene.
HL60 cells were transfected with the plasmids using a nucleofector 
(Lonza) as described according to the manufacturer’s instructions (usually 
40% cells were transfected). 5 µM DFO was added in culture medium 48 h 
after transfection and flow cytometry analysis was realized 24 h later on the 746 Iron chelation drives AML differentiation | Callens et al.
Figure 9.  Iron chelation therapy in combination with VD treatment induced blast differentiation in a refractory AML/MDS patient.  
(a) Curves representing the blood counts during treatment. The diagnosis and the beginning of the combination therapy are represented with arrows.  
(b) Plasma calcium concentration during the treatment. Horizontal bars represent minimal and maximal physiological levels of calcemia. (c) MGG-stained 
blood cytosmears during treatment. At diagnosis, undifferentiated blasts were predominantly observed in MGG-stained blood cytosmears. 1 mo after JEM VOL. 207, April 12, 2010 
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beginning treatment, the blasts started to present signs of monocyte differentiation, such as nuclear deformation, cytoplasm enlargement, and the  
presence of vacuoles. After 3 mo of treatment, undifferentiated blasts were replaced by monocytoid blasts and pro-monocytes. After 4 mo,  
some monoblasts were still detected, but mature monocytes were predominantly observed. Representative photos of each blood cytosmears are shown. 
(d) The differentiation potential of blasts treated with combination therapy was evaluated in circulating cells after 3 mo of treatment. PBMCs were  
isolated, and the cell populations were sorted as follows: blasts (CD34+CD117+); monocytes (CD34CD117CD4lowCD14+); and lymphocytes and NK cells 
(CD34CD117CD14). The cells were further processed for cytogenetic analysis. (e) FISH analysis. Representative images of chromosomes 8 (green) and 
12 (red) probed by fluorescent in situ hybridization demonstrating the trisomy 8 present in the monocytes. (f) Percentage of trisomy 8–positive cells in 
sorted fractions from d, demonstrating that the monocytes, but not the lymphocytes and NK cells, originated from the blast pool.
 
basis of the EmGFP (for miRNA) or EGFP (for protein constructs) expres­
sion. Validation of miRNA constructs was performed on CHO cells electro­
porated with each miRNA­containing plasmid using the nucleofector and 
analyzed in Western blotting after 24 h to validate the constructs.
Cytogenetic analysis. FISH was performed using standard protocols with 
specific centromeric probes for chromosome 8 (pZ8.4) and chromosome   
12 (pBR12; provided by M. Rocchi, University of Bari, Bari, Italy) used   
as control.
RNA isolation, real-time quantitative PCR, and transcriptome analy-
sis.  Total  RNA  from  time­matched  controls  and  treated  samples  was   
extracted using NucleoSpin RNA II (Macherey­Nagel). After DNase treat­
ment, first­strand cDNA was synthesized using SuperScript II reverse tran­
scription (Invitrogen). Quantitative real­time PCR was performed using a 
Chromo­IV PCR System (MJ Research), and the PCR products were 
quantified  using  Sybr  Green  Technology  (Jumpstart  MasterMix;  Sigma­ 
Aldrich). The results of the real­time quantitative PCR were analyzed using 
the delta­delta Ct method (Livak and Schmittgen, 2001). The complete list 
of primer sequences is available in Table S4.
For  the  microarrays,  the  Agilent  44  K  Whole  Human  Genome 
(G4112A) long (60 bp) oligonucleotide microarray and the dual­color analy­
sis method were used with probes from the treated samples and from refer­
ence RNA that were differentially labeled with cyanine 5 and cyanine 3. 
These microarrays have 44,290 features with 41,000 distinct oligonucle­
otides belonging to 33,715 sequences defined by their accession number. 
cRNA from each treated sample was labeled with Cy3­cytidine triphosphate 
(CTP) and the untreated HL60 RNA reference pool with Cy5­CTP for   
direct comparison. Reverse transcription, linear amplification, cRNA label­
ing, and cRNA purification were performed with the linear amplification kit 
(Agilent Technologies). The microarray data were mainly analyzed with the 
Resolver software (Merck). All data were filtered to eliminate low­intensity 
values <50 arbitrary units for both colors. The microarray data analyzed in 
this paper have been submitted to the Array Express data repository at the 
European Bioinformatics Institute (http://www.ebi.ac.uk/arrayexpress/) 
under accession no. E­TABM­925.
Tumor xenografts. For tumor establishment, 5 × 106 HL60 or 2.5 × 106 
OCI­AML3 cells were mixed with Matrigel (1:1, vol/vol) and injected sub­
cutaneously into 8–10­wk­old female athymic Nude mice. The mice were 
then injected i.p. with A24 (40 mg/kg on day 1), DFO (20 mg/day, 5–7×/wk), 
VD (1 µg, 2×/wk), and the combination of DFO and VD or PBS as a   
vehicle control. The tumor growth was measured as previously described 
(Lepelletier et al., 2007).
Immunohistochemistry. Serial sections (3 µm) in paraffin blocks were 
deparaffinized in xylene and hydrated in a graded series of alcohol. Staining 
was  performed  using  the  Immunohistochemical  Autostainer  (Laboratory   
Vision  Corporation)  with  primary  antibodies  against  CD11b  (Sigma­ 
Aldrich, 1:200), p­ERK, and p­JNK (Cell Signaling Technology, 1:200), 
biotinylated anti­Ig, and streptavidin­peroxidase. The antibody binding was 
developed in PBS with 0.05% DAB and 0.003% H2O2. Hematoxylin­eosin 
(HE)–stained sections were used to evaluate cytomorphology and to detect 
apoptotic cells with condensed nuclei. Apoptosis was assessed by the TUNEL 
technique according to the manufacturer’s instructions (Roche). The images 
were obtained using a microscope (DM­2000; Leica) equipped with a digi­
tal camera (DFC320; Leica) and IM50 software. Data were quantified us­
ing Image J software (National Institutes of Health).
Cord  blood  cell  cultures  and  methylcellulose  colony-forming   
assays. CD34+ cord blood cells were isolated by immunomagnetic separa­
tion (Miltenyi Biotec) and cultured in IMDM supplemented with 15%   
BIT 9500 (Stem Cell Technologies), 100 ng/ml SCF, 10 ng/ml IL­3,   
25 ng/ml G­CSF, and 10 ng/ml GM­CSF for myelomonocytic differenti­
ation  (all  cytokines  were  purchased  from  R&D  Systems).  10  µg/ml   
A24, 5 µM DFO, or 3 µM DFX was added iteratively every 3 d in the   
culture medium.
For colony­forming assays, 103 CD34+ cells were plated in quadrupli­
cate in semisolid methylcellulose medium (H4434; Stem Cell Technologies) 
in the presence or absence of 10 µg/ml A24, 5 µM DFO, or 3 µM DFX.   
At day 14, colonies containing >50 cells were counted and classified as gran­
ulocyte colony (CFU­G), monocyte­macrophage colony (CFU­M), mixed 
granulocyte­monocyte colony (CFU­GM), or erythroid colony (CFU­E). 
The colonies were counted by standard criteria in 60­mm gridded scoring 
dishes with cross marks (Stem Cell Technologies) under an inverted micro­
scope. To verify if iron deprivation leads to an altered formation of myelo­
monocytic colonies, we represented the ratio between CFU­G and CFU­M 
in both nontreated and treated groups.
Analysis of cellular differentiation and apoptosis. Cell differentiation 
was determined by the following criteria: cell morphology was evaluated   
after MGG staining. Esterase activity was detected using the LEUCOGNOST 
EST kit (Merck). The expression of CD11b (IM2581U; Beckman Coulter) 
and CD14 (A07765; Beckman Coulter) was evaluated by flow cytometry 
(FACSCalibur;  BD).  Cell  death  was  evaluated  using  the  annexin­V/
propidium iodide (PI) double staining kit (BD) according to the manu­
facturer’s instructions.
Immunoblotting.  All  experiments  were  made  with  serum­starved  cells 
(12–16 h) to avoid detection of constitutive phosphorylation induced by 
growth factors (Wang and Proud, 2007). Whole cell extracts were prepared 
as described previously (Amir­Moazami et al., 2008). In brief, cell pellets (107 
cells) were washed twice with PBS and then resuspended in 1 ml of lysis   
buffer (20 mM Tris­HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 1% Triton X­100, 2.5 mM sodium pyrophosphate, 1 mM h­glycero­
phosphate, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml 
leupeptin, and 1 µg/ml aprotinin). The protein concentration was deter­
mined  using  the  BCA  method  (Thermo  Fisher  Scientific)  and  an  equal 
amount of SDS sample buffer containing 150 mM Tris­HCl, pH 6.8, 30% 
glycerol, 3% SDS, 1.5 mg/ml bromophenol blue, and 100 mM DTT was 
then added to each sample. For immunoblotting, 40 µg of protein was sepa­
rated in 4–12% or 7% SDS­PAGE and transferred onto a PVDF membrane. 
The blots were first probed with an anti­phospho protein, p­ERK (Thr202/
Tyr204), p­JNK, p­p38 (all from Cell Signaling Technology), or p­VDR 
(Ab63572; Abcam) antibody. The membranes were stripped, dried, and 
probed with an antibody against total ERK (Cell Signaling Technology), 
VDR (Ab39990; Abcam), or HSC70 (sc­71270; Sants Cruz Biotechnology, 
Inc.). The protein bands were visualized using a chemiluminescence system.748 Iron chelation drives AML differentiation | Callens et al.
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Analysis of combined drug effects. CD14 expression was used to evalu­
ate the combined efficacy of DFO, vitamin D, and mAb A24. In each   
experiment, HL60 cells were treated with serial dilutions of each agent indi­
vidually and with a fixed ratio of two agents simultaneously. The results 
were analyzed using the median effect/CI isobologram method of Chou 
and Talalay (1984). F(a) is the fraction of cells affected (i.e., CD14+) and f(u) 
is the fraction of cells unaffected (i.e., CD14). F is the ratio f(a)/f(u) and   
D is the drug concentration. Log(F) was plotted against log(D). The dose   
response is displayed as a linear regression line and the x­intercept corre­
spond to the log(IC50). The CI was defined as follows: CI = (D)1/(Dx)1 + 
(D)2/(Dx)2, where (Dx)1 and (Dx)2 are the doses required to achieve a given 
effect level for each drug, i.e., a specified value of f(a). (D)1 and (D)2 are the 
doses of each drug in a given mixture which gives the same f(a). When CI 
values are 1, <1, or >1, it may be concluded that summation, synergism, or 
antagonism, respectively have been observed at the particular level exam­
ined. The CI was calculated based on the conservation assumption of mutu­
ally nonexclusive drug interactions.
Statistical analysis. The data are expressed as the mean ± SEM. Statistical 
analyses were performed using Prism 5 software (GraphPad Software, Inc.). 
We used the Student’s t test or the Mann­Whitney test to compare two 
groups, and multigroup comparisons were made using a one­way ANOVA 
followed by a post­hoc Bonferroni test. We used the Kruskal­Wallis test fol­
lowed by a post­hoc Dunn test for nonparametric comparisons, where indi­
cated. To compare tumor­free animal curves, the Log­rank test was used. 
The results were considered statistically significant at a p­value <0.05 (*), 
<0.01 (**), or <0.001 (***).
Online supplemental material. Fig. S1 shows that iron deprivation in­
duces morphological and phenotypical modifications of monocytic cells   
related to cellular differentiation. Fig S2 shows that iron deprivation inhibits 
proliferation and induces differentiation of AML blasts. Fig. S3 shows the in 
vitro granulocytic cord blood progenitor differentiation system. Fig. S4 shows 
detection of intracellular LIP and ROS in AML cells. Fig. S5 shows the 
efficacy of miRNA constructs targeting c­JUN, JNK1, and JNK2. Fig. S6 
shows determination of the synergic versus additive effect of the combined 
DFO/VD and A24/VD therapies on cell differentiation. Fig. S7 shows that 
A24 and iron chelators do not synergize with ATRA to induce differen­
tiation. Fig. S8 shows the anti­tumor effect of iron deprivation and iron 
deprivation combined with VD in Nude mice xenografted with AML cell 
lines.  Online  supplemental  material  is  available  at  http://www.jem.org/ 
cgi/content/full/jem.20091488/DC1.
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